Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

[EX Q]: Evolocumab met the main goal of a late-stage trial titled RUTHERFORD-2 by lowering “bad” LDL cholesterol levels when tested against a placebo on 329 patients. Amgen, the world’s biggest biotechnology company, is testing evolocumab widely on a variety of subpopulations. The RUTHERFORD-2 study included patients with familial hypercholesterolemia, an inherited condition that causes high levels of “bad” LDL cholesterol starting at birth. Specifically, patients in the study had heterozygous familial hypercholesterolemia, which is one of the most common genetic disorders affecting about one out of every 300 to 500 people worldwide, according to Amgen. The company on Tuesday reported positive results from a fourth late-stage study of evolocumab, for which it plans to begin seeking approvals this year. The drug is intended for people who cannot tolerate widely used statins, or who are unable to get their LDL levels low enough despite using high potency statins, such as AstraZeneca’s Crestor. Amgen’s shares closed at $120.89 on the Nasdaq on Thursday.
[EX A]: Amgen's cholesterol fighter succeeds in fifth late-stage study.

[EX Q]: "The article states that the costs are “generally … close to $45,000.” The news story notes in a sentence that hip replacement has a success rate of more than 90%, and defines “success” as “relatively pain-free mobility.” The article also clearly states why this new device was developed — to provide longer lifetime use prior to device failure. It quantifies this benefit vaguely, saying the device is ""much more durable"" and lasts ""much longer."" The news story focuses on one main harm—squeaking in hip implants made of ceramic—and provides estimates of its prevalence. A spokesperson for the hip maker points out that hip replacement has other potential risks as well, including infection, dislocation, and leg-length discrepancy. The news story makes it fairly clear that the research it is citing is from cohort studies. The first mention of the prevalence of squeaking in ceramic hip implants appears to cite the highest known estimate—7% of ceramic implants in one study of 143 patients. Only later do readers discover that other studies suggest the prevalence of the problem may be much smaller, from 3% (in a study of 1500 people) to less than 1%. This is not disease mongering, but it could cause some people to fear ceramic hip implants more than may be justified. In addition, the Times article says no squeaking occurred in patients with metal and plastic implants. But a recent 2007 review in the Journal of Bone & Joint Surgery (JBJS) reported that squeaking in similar implants made out of metal and plastic occurred in 4% of patients. (JBJS 2007;89:1874-85) If the JBJS review is accurate, the news story would be misleading. Unfortunately, the JBJS failed to support its own contention with a complete reference. The story cites 4 patients, 4 surgeons, a spokesperson for implant maker Stryker, and a lawyer representing aggrieved patients. All in all, they provide a balance of viewpoints. The story mentions a conflict of interest for one surgeon. It appears that 2 of the patients are clients of the lawyer. The story points out that the alternatives to a ceramic total hip replacement include hip replacements with implants made from metal and plastic. It doesn’t mention whether there are nonsurgical alternatives to hip replacement, but this is beyond the scope of the story. The story does not explicitly state that ceramic hip replacements are approved by the FDA, but with “tens of thousands” implanted, it’s clear that surgeons’ adoption of the devices is widespread. The FDA’s warning to implant maker Stryker about squeaking suggests the devices may not be perfect, but are approved. The story notes that Stryker introduced ceramic hip implants into the U.S. in 2003. The story cites several sources and does not appear to rely solely or largely on a news release."
[EX A]: That Must Be Bob. I Hear His New Hip Squeaking.

[EX Q]: The girl’s body was repatriated to Congo for a funeral upon the request of her father, according to Uganda’s health ministry. The girl, who was traveling with her mother, was identified at a border screening Wednesday as a possible Ebola patient and isolated. Although cases of cross-border contamination have been rare, this case highlights the risk of Ebola spreading across the border into neighboring Uganda and Rwanda. Borders in the region are often porous, and many people traveling at night use bush paths to cross over. In June, a family of Congolese with some sick family members crossed into Uganda via a bush path. Two of them later died of Ebola, and the others were transferred back to Congo. “It is critical we continue to be on high alert in high-risk areas and empower communities to be prepared in order to contain the virus,” the International Federation of Red Cross and Red Crescent Societies said. Uganda has had multiple outbreaks of Ebola and hemorrhagic fevers since 2000. Because the 9-year-old Ebola victim passed through an official entry point this week, Ugandan health authorities believe she had no contact with any Ugandan. But at least five other Congolese, including attendants to patients, who shared an ambulance with the sick girl have been identified by Ugandan officials as Ebola contacts. Four of them have since been taken back to Congo for vaccination and monitoring, said Joyce Moriku Kaducu, Ugandan minister of state in charge of primary health care. Ebola has killed nearly 2,000 people in eastern Congo since August 2018. The disease is spread through contact with the bodily fluids of an infected person. WHO said Friday that cases have reached 3,000 in Congo, with 1,893 confirmed deaths and about 900 survivors. On average, 80 people per week are sickened by the virus, which has infected most people in Congo’s North Kivu province. The Ebola outbreak in eastern Congo hasn’t shown signs of slowing down despite new treatments and vaccines given to more than 200,000 people in the region and the use of two therapeutic treatments being used as part of a clinical trial. Insecurity has been one factor in a region where rebel groups have fought for control of mineral-rich lands for decades. Ebola also has spread because of mistrust by communities who have also staged attacks against health workers. Many people in eastern Congo don’t trust doctors and other medics. “One year into the response, the lack of community acceptance remains the single greatest obstacle to containing the outbreak,” said Bob Kitchen, Vice President of Emergencies at the International Rescue Committee. “Building trust with the community doesn’t just mean dialogue with the affected population. It means working with the community to adapt the response and address the overall needs they are facing inside and outside of the Ebola outbreak.” WHO Director-General Tedros Adhanom Ghebreyesus will travel this weekend to Congo with U.N. Secretary-General Antonio Guterres and senior officials, including Dr. Matshidiso Moeti, WHO regional director for Africa. On Friday, he called on partners to increase their presence in the field. “Our commitment to the people of the Democratic Republic of the Congo is that we will work alongside them to stop the Ebola outbreak,” Ghebreyesus said. “Our commitment also means strengthening the health systems to give them all the other things they need. Building strong systems is what will protect people, communities and the world.” ___ Maliro reported from Beni, Congo. AP writers Carley Petesch in Dakar, Senegal, and Jamey Keaten in Geneva contributed to this report.
[EX A]:
Uganda: 9-year-old girl from Congo dies of Ebola.